|Bid||71.28 x 38700|
|Ask||71.36 x 105300|
|Day's range||70.96 - 72.78|
|52-week range||55.44 - 91.74|
|Beta (3Y monthly)||1.28|
|PE ratio (TTM)||11.11|
|Earnings date||30 Jul 2019|
|Forward dividend & yield||1.17 (1.66%)|
|1y target est||80.61|
Fresenius reported a rise in first-quarter sales and operating profit on Thursday, helped by growth at its generic infusion drugs and dialysis units, as its troubled German hospital business showed signs of stabilisation. Currency-adjusted quarterly sales rose 5 percent to 8.5 billion euros (£7.3 billion), helped by growth at its Kabi infusion unit and separately listed Fresenius Medical Care. "All four Fresenius business segments have developed in line with our expectations, putting us well on course to meet our targets for the year," Chief Executive Stephan Sturm said.
The Securities and Exchange Commission on Friday announced that Fresenius Medical Care AG & Co KGaA , a German medical device company, has agreed to pay over $231 million to settle charges brought by the Department of Justice and SEC. Fresenius was found to have violated the Foreign Corrupt Practices Act by falsifying documents as well as contracts and funneling bribes through third-party intermediaries. FMC paid nearly $30 million in bribes to government officials and others to procure business, the company said. "By engaging in widespread bribery schemes across multiple countries, the company prioritized profits over compliance in its dealings with foreign government officials," said Tracy Price, deputy chief of the SEC Enforcement Division's FCPA Unit, in a statement.
If you want to know who really controls Fresenius Medical Care AG & Co. KGaA (ETR:FME), then you'll have to look at the makeup of its share registry. Large companiesRead More...
The goal is to reduce the $114 billion paid by the U.S. government each year to treat chronic kidney disease and end-stage renal disease, a top area of spending. The U.S. Centers for Medicare and Medicaid Services (CMS), which provides Medicare health benefits to more than 55 million Americans, is looking at a trial payment design that would improve care in the early stages of kidney disease, increase access to kidney transplants and favor home dialysis over clinic-based treatment, CMS head Seema Verma told Reuters in an interview.
(Adds Ophir Energy, Alitalia, Bristol-Myers Squibb, Cemex, Tilray, Magellan Health, Verus Petroleum, Owens & Minor; Updates Bank Audi, Sainsbury) Feb 20 (Reuters) - The following bids, mergers, acquisitions ...
Germany's Fresenius Medical Care (FMC) said on Wednesday it has won the green light from U.S. regulators to acquire U.S. home dialysis equipment maker NxStage and expects the deal to close in the next few days. FMC agreed to buy NxStage in August 2017 for $2 billion but the deal has been held up due to competition concerns and most recently the U.S. government shutdown. "Very early this morning, we were notified the Federal Trade Commission has approved our NxStage deal," Chief Executive Rice Powell told reporters.
Encouraging signs from trade talks between the world's two biggest economies helped boost European shares on Wednesday while the threat of a blocked merger deal sank Sainsbury's shares. Germany's trade-sensitive ...
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! While some investors are already well versed in financial metricsRead More...
Does the January share price for Fresenius Medical Care AG & Co. KGaA (ETR:FME) reflect it's really worth? Today, I will calculate the stock's intrinsic value by taking the expected Read More...
Germany's Fresenius Medical Care (FMC) said on Tuesday it had agreed to extend the deadline for its planned $2 billion takeover of U.S. home dialysis equipment maker NxStage Medical Inc until August 6. FMC said the extension had been agreed due to the recent U.S. government shutdown which interrupted the Federal Trade Commission's (FTC) ability to review the transaction.
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Miscellaneous28.12.2018 / 22:18 The issuer is solely responsible for the content of this announcement.Fresenius Medical Care, the world's largest provider of dialysis products and services, is still in the process of seeking approval by the U.S. Federal Trade Commission (FTC) for its acquisition of NxStage Medical, Inc. ("NxStage") and therefore now expects the transaction to close in early 2019. ...
Investors pursuing a solid, dependable stock investment can often be led to Fresenius Medical Care AG & Co. KGaA (ETR:FME), a large-cap worth €18b. Big corporations are much sought after Read More...
Fresenius Medical Care AG & Co. KGaA / Total Voting Rights Announcement12.12.2018 / 16:10Total Voting Rights Announcement transmitted by DGAP - a service of EQSGroup AG.The issuer is solely responsible for the content of this announcement.---------------------------------------------------------------------------Publication of total number of voting rights1. Details of issuer Fresenius Medical Care AG & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Germany2. Type of capital measure Type of capital measure Date of status / date of effect X Conditional capital increase (Sec. 41 5 Dec 2018 ...
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Forecast06.12.2018 / 23:16 The issuer is solely responsible for the content of this announcement.
Fresenius Medical Care AG & Co. KGaA / Key word(s): ForecastFresenius Medical Care AG & Co. KGaA gives early preliminary indicative guidance for 201906-Dec-2018 / 22:35 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Fresenius Medical Care, the world's largest provider of dialysis products and services, has decided to update the market early on its indicative preliminary assumptions for the business development in 2019. ...
DGAP-News: Fresenius Medical Care AG & Co. KGaA / Key word(s): Acquisition05.12.2018 / 11:35 The issuer is solely responsible for the content of this announcement.